Last reviewed · How we verify

NCT03404089: MON4STRAT

Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.

Terminated NA Last updated 19 January 2023
What this trial tests

NA trial testing pharmacokinetic device in Intensive Care Unit Syndrome in 13 participants. Terminated before completion.

Timeline
18 April 2018
Primary endpoint
30 June 2019
30 June 2019

Quick facts

Lead sponsorUniversity Hospital, Lille
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment13
Start date18 April 2018
Primary completion30 June 2019
Estimated completion30 June 2019
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Lille

Who can join

Under 18, any sex, with Intensive Care Unit Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluate the capacity of the MON4STRAT device for drug monitoring of β- lactam antibiotic concentrations in newborns, children, and adolescents admitted in intensive care units with a health care-associated infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intensive Care Unit Syndrome

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03404089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing